In 2023, ScinoPharm Taiwan completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, ScinoPharm Taiwan has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020-2019 |
|---|---|---|---|---|
Total Scope 1 | 4,292.54a | 3,262.84a | 3,162a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 17,067.97a | 16,045.18a | 19,739a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 41.3304a | 30.7176a | 31.7333a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of ScinoPharm Taiwan amounted to 21,360.51 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of ScinoPharm Taiwan increased by 10.63%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2023, the total Scope 1 emissions of ScinoPharm Taiwan were 4,292.54 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, ScinoPharm Taiwan's Scope 1 emissions have increased by 61.5%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2022), ScinoPharm Taiwan's Scope 1 emissions increased by 31.56%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2023, ScinoPharm Taiwan reported Scope 2 greenhouse gas (GHG) emissions of 17,067.97 tCO₂e without specifying the calculation method.a
Since 2020, ScinoPharm Taiwan's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 17.32%, reflecting a declining long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2022), ScinoPharm Taiwan's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that ScinoPharm Taiwan's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2023, ScinoPharm Taiwan reported its Scope 2 emissions using an unspecified methodology.a
In 2023, ScinoPharm Taiwan reported Scope 1 greenhouse gas (GHG) emissions of 4,292.54 tCO₂e and total revenues of USD 104 millions. This translates into an emissions intensity of 41.33 tCO₂e per millions USD.a
In 2023, ScinoPharm Taiwan reported a Scope 1 emissions intensity of 41.33 tCO₂e per millions USD. Compared to the peer group median of 8.57, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2023, ScinoPharm Taiwan ranked 20 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places ScinoPharm Taiwan among the least efficient performers, with one of the highest emissions intensities in its sector.a